Jurnista

Hydromorphone, the active ingredient in Jurnista, is an opioid analgesic presented as an unknown/unknown for oral use. It is employed to manage moderate to severe acute pain, postoperative pain, and cancer‑related pain in adult patients.

GNH USA supplies Jurnista as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Hydromorphone is an opioid analgesic used for pain management across several clinical settings.

- Moderate to severe acute pain: provides rapid relief of intense pain episodes. - Postoperative pain: helps control pain following surgical procedures. - Cancer‑related pain: alleviates persistent pain associated with malignant disease.

Hydromorphone may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Constipation: reduced gastrointestinal motility. - Nausea: feeling of queasiness or urge to vomit. - Drowsiness: increased sleepiness or fatigue. - Dry mouth: reduced salivary flow. - Dizziness: light‑headed sensation. - Pruritus: mild itching of the skin.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing. - Severe hypotension: marked drop in blood pressure. - Dependence or addiction: potential for misuse with prolonged use. - Seizures: rare occurrence of convulsive episodes. - Anaphylaxis: life‑threatening allergic reaction. - QT prolongation: abnormal heart rhythm in susceptible individuals.

When prescribing hydromorphone, clinicians should consider several safety measures.

- Assess pain severity: confirm that pain is moderate to severe before initiating therapy. - Evaluate respiratory function: monitor patients with compromised breathing. - Review opioid history: avoid use in individuals with known opioid dependence. - Adjust for renal/hepatic impairment: dose may need modification in organ dysfunction. - Educate on constipation: advise prophylactic laxatives and hydration. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Hydromorphone can interact with other medications, influencing its safety and efficacy.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, barbiturates): may cause profound respiratory depression. - MAO inhibitors: can precipitate severe hypertension or serotonin syndrome. - CYP3A4 inhibitors (e.g., ketoconazole): increase hydromorphone plasma levels.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine): may modestly raise drug concentrations. - Anticholinergics: may worsen constipation. - Diuretics: can enhance hypotensive effects. - Alcohol: additive sedative effect, requires caution.